Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum

Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum

Abstract In this study, we report the in vivo efficacy of 14-hydroxylunularin evaluated in BALB/c mice experimentally infected with promastigotes of Leishmania infantum (syn L. chagasi ), the major causative agent of visceral leishmaniasis in Latin America. Seven days post-infection, treatment with...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology international Vol. 64; no. 5; pp. 295 - 298
Main Authors: Serna, Ma. Elva, Maldonado, Marisel, Torres, Susana, Schinini, Alicia, Peixoto de Abreu Lima, Alejandro, Pandolfi, Enrique, Rojas de Arias, Antonieta
Format: Journal Article
Language:English
Published: Netherlands 01-10-2015
Subjects:
Animals
Anthelmintics - pharmacology
Bibenzyls - pharmacology
Disease Models, Animal
Gastroenterology and Hepatology
Infectious Disease
Leishmania infantum - drug effects
Leishmaniasis, Visceral - drug therapy
Leishmaniasis, Visceral - parasitology
Liver - parasitology
Male
Meglumine - pharmacology
Mice
Mice, Inbred BALB C
Organometallic Compounds - pharmacology
Phenols - pharmacology
Spleen - parasitology
14-hydroxylunularin
BALB/c mice
Leishmania infantum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In this study, we report the in vivo efficacy of 14-hydroxylunularin evaluated in BALB/c mice experimentally infected with promastigotes of Leishmania infantum (syn L. chagasi ), the major causative agent of visceral leishmaniasis in Latin America. Seven days post-infection, treatment with 14-hydroxylunularin started and it was administered by oral and subcutaneous routes in doses of 10 and 25 mg/kg of weight for ten days using Glucantime® as reference drug. In the liver, the evaluated compound showed parasite reduction above 90% by both administration routes being the oral route the most effective at both doses. Significant decreased numbers of parasites were also observed when the treated group was compared with the control group (p ≤ 0.05). The subcutaneous route presented a remarkable difference with at least 80% parasite suppression in liver and spleen at 10 mg/kg dose and 90% in liver at 25 mg/kg. The leishmanicidal activity of 14-hydroxylunularin against L. infantum revealed by this study is another evidence in favor of this compound as a potential candidate for the development of a new oral treatment for leishmaniasis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1383-5769
1873-0329
DOI:10.1016/j.parint.2015.03.005